Calithera Biosciences, Inc. (CALA)
USD 0.01
(4900.0%)
USD 0.01
(4900.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 | 40.68 Million USD | -43.38% |
| 2021 | 74.3 Million USD | -18.69% |
| 2020 | 91.38 Million USD | -1.62% |
| 2019 | 92.89 Million USD | 16.8% |
| 2018 | 79.53 Million USD | 42.94% |
| 2017 | 55.64 Million USD | 45.15% |
| 2016 | 38.33 Million USD | 16.8% |
| 2015 | 32.81 Million USD | 51.09% |
| 2014 | 21.72 Million USD | 75.48% |
| 2013 | 12.37 Million USD | 55.21% |
| 2012 | 7.97 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 Q2 | 11.37 Million USD | -17.72% |
| 2022 Q3 | 9.52 Million USD | -16.26% |
| 2022 Q4 | 7.34 Million USD | -22.88% |
| 2022 Q1 | 13.82 Million USD | -24.59% |
| 2022 FY | 42.07 Million USD | -43.38% |
| 2021 Q1 | 20.76 Million USD | -8.37% |
| 2021 Q4 | 18.33 Million USD | 2.42% |
| 2021 Q2 | 17.3 Million USD | -16.66% |
| 2021 Q3 | 17.9 Million USD | 3.43% |
| 2021 FY | 74.3 Million USD | -18.69% |
| 2020 FY | 91.38 Million USD | -1.62% |
| 2020 Q4 | 22.66 Million USD | -1.04% |
| 2020 Q2 | 20.75 Million USD | -17.23% |
| 2020 Q3 | 22.9 Million USD | 10.36% |
| 2020 Q1 | 25.07 Million USD | 11.66% |
| 2019 Q4 | 22.45 Million USD | 6.28% |
| 2019 Q2 | 24.91 Million USD | 2.09% |
| 2019 FY | 92.89 Million USD | 16.8% |
| 2019 Q1 | 24.4 Million USD | 20.66% |
| 2019 Q3 | 21.12 Million USD | -15.19% |
| 2018 Q4 | 20.22 Million USD | 3.68% |
| 2018 Q2 | 20.8 Million USD | 9.48% |
| 2018 Q1 | 19 Million USD | 1.09% |
| 2018 FY | 79.53 Million USD | 42.94% |
| 2018 Q3 | 19.5 Million USD | -6.23% |
| 2017 Q4 | 18.79 Million USD | 35.15% |
| 2017 Q2 | 12.99 Million USD | 30.58% |
| 2017 Q1 | 9.94 Million USD | 3.58% |
| 2017 FY | 55.64 Million USD | 45.15% |
| 2017 Q3 | 13.9 Million USD | 7.06% |
| 2016 Q1 | 9.65 Million USD | 18.81% |
| 2016 FY | 38.33 Million USD | 16.8% |
| 2016 Q4 | 9.6 Million USD | 11.26% |
| 2016 Q3 | 8.63 Million USD | -17.33% |
| 2016 Q2 | 10.44 Million USD | 8.12% |
| 2015 FY | 32.81 Million USD | 51.09% |
| 2015 Q4 | 8.12 Million USD | -9.18% |
| 2015 Q3 | 8.95 Million USD | 13.67% |
| 2015 Q2 | 7.87 Million USD | 0.09% |
| 2015 Q1 | 7.86 Million USD | 15.05% |
| 2014 Q2 | 5.49 Million USD | 32.34% |
| 2014 FY | 21.72 Million USD | 75.48% |
| 2014 Q4 | 6.83 Million USD | 30.47% |
| 2014 Q3 | 5.24 Million USD | -4.57% |
| 2014 Q1 | 4.15 Million USD | 1.52% |
| 2013 Q4 | 4.08 Million USD | 23.21% |
| 2013 Q3 | 3.31 Million USD | 0.0% |
| 2013 FY | 12.37 Million USD | 55.21% |
| 2012 FY | 7.97 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| America Great Health | 661.23 Thousand USD | -6053.513% |
| Ampio Pharmaceuticals, Inc. | 9.26 Million USD | -339.027% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -35.662% |
| Biora Therapeutics, Inc. | 67.14 Million USD | 39.403% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -156.826% |
| Better Therapeutics, Inc. | 38.26 Million USD | -6.343% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -228.33% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -20.225% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -18.217% |
| Evelo Biosciences, Inc. | 108.46 Million USD | 62.487% |
| Evolutionary Genomics, Inc. | 992.8 Thousand USD | -3998.371% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -24.855% |
| Galera Therapeutics, Inc. | 46.95 Million USD | 13.337% |
| Innovation1 Biotech Inc. | 1.21 Million USD | -3249.749% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -104.064% |
| Molecular Templates, Inc. | 63.09 Million USD | 35.507% |
| Navidea Biopharmaceuticals, Inc. | 13.93 Million USD | -192.063% |
| NexImmune, Inc. | 28.16 Million USD | -44.454% |
| Orgenesis Inc. | 45.75 Million USD | 11.076% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -58.65% |
| Point of Care Nano-Technology, Inc. | 73.41 Thousand USD | -55322.524% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -152.018% |
| Scopus BioPharma Inc. | 11.71 Million USD | -247.328% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 89.918% |
| Statera Biopharma, Inc. | 28.82 Million USD | -41.137% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -114.956% |
| Trevena, Inc. | 38.41 Million USD | -5.925% |
| Vaxxinity, Inc. | 56.05 Million USD | 27.407% |
| Vaccinex, Inc. | 23.45 Million USD | -73.477% |
| Vicapsys Life Sciences, Inc. | 1.04 Million USD | -3786.328% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | 19.734% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -459.328% |